

OCT 11 2006
PATENT & TRADEMARK OFFICE

IDS Form PTO/SB/08: Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/721,022
		Filing Date	November 25, 2003
		First Named Inventor	Lukas-Laskey et al.
		Art Unit	1614
		Examiner Name	P. Spivack
		Attorney Docket Number	04012.0384-00000

Sheet	1	of	1
-------	---	----	---

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁹
PS		CLELAND et al., "Clinical trials update from the American College of Cardiology: darbapoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND," European Journal of Heart Failure, 8, pp. 326-329, 2006.	
PS		SHADDY et al., "The pediatric randomized carvedilol trial in children with chronic heart failure: Rationale and design," American Heart Journal, vol. 144, no. 3, pp. 383-389, September 2002.	
PS		Summary Report, Study No.: SK&F-105517/321, "A Multicenter, placebo-controlled, 8-month study of the effect of twice daily carvedilol in children with congestive heart failure due to systemic ventricular systolic dysfunction," pp. 1-9, July 2006.	
PS		Clinical Study Report, Study No.: SK&F-105517/321, "A Multicenter, placebo-controlled, 8-month study of the effect of twice daily carvedilol in children with congestive heart failure due to systemic ventricular systolic dysfunction," abstract and cover pp. 1-4 and Clinical Study Report pp. 1-238, 266, 342-360, July 17, 2006.	
PS		Summary Report, Study No.: SK&F-105517/396, "A Multicenter Open-label Extension Study to Evaluate the Safety of Twice Daily Oral Carvedilol in Pediatric Subjects with Chronic Heart Failure," abstract and cover pages pp. 1-4, 2005.	
PS		Clinical Study Report, Study No.: SK&F-105517/396, "A Multicenter Open-label Extension Study to Evaluate the Safety of Twice Daily Oral Carvedilol in Pediatric Subjects with Chronic Heart Failure," abstract and cover pages pp. 1-4 and Clinical Study Report pp. 1-135., August 2006.	

Examiner Signature	P. Spivack	Date Considered	11/4/06
--------------------	------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.